<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347493">
  <stage>Registered</stage>
  <submitdate>19/09/2011</submitdate>
  <approvaldate>19/09/2011</approvaldate>
  <actrnumber>ACTRN12611000994987</actrnumber>
  <trial_identification>
    <studytitle>Effect of Mupirocin in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial</studytitle>
    <scientifictitle>Effect of Mupirocin on S.aureus infection in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Rhinosinusitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mupirocin nasal rinses, 0.05% twice daily for 4 weeks.</interventions>
    <comparator>Placebo (saline rinses)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>S.aureus infection, as assessed by endoscopically-guided nasal swab</outcome>
      <timepoint>At end of 4-week treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Signs and symptoms of chronic rhinosinusitis, as assessed by the sinonasal outcome test (SNOT-20) and the Lund-Kennedy endoscopic examination score.</outcome>
      <timepoint>At end of 4-week treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with surgically-recalcitrant, S.aureus-positive chronic rhinosinusitis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Mupirocin allergy.
Augmentin Duo allergy.
Multiple bacterial species on culture.
MRSA.
Mupirocin-resistant S.aureus.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>18/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital</primarysponsorname>
    <primarysponsoraddress>28 Woodville Road, Woodville South, South Australia
5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Otolaryngology Head &amp; Neck Surgery</fundingname>
      <fundingaddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South, South Australia
5011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We hypothesise that Mupirocin nasal rinses are more efficacious compared to placebo in patients that are bothered by persistent S.aureus infection despite complete sinus surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics of Human Research Committe (TQEH &amp; LMH)</ethicname>
      <ethicaddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA 5011</ethicaddress>
      <ethicapprovaldate>16/06/2009</ethicapprovaldate>
      <hrec>2008171</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Josh Jervis-Bardy</name>
      <address>Department of Otolaryngology Head &amp; Neck Surgery
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
South Australia 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227419</fax>
      <email>josh.bardy@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Josh Jervis-Bardy</name>
      <address>Department of Otolaryngology Head &amp; Neck Surgery
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
South Australia 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227419</fax>
      <email>josh.bardy@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Josh Jervis-Bardy</name>
      <address>Department of Otolaryngology Head &amp; Neck Surgery
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
South Australia 5011</address>
      <phone>+61 8 82226000</phone>
      <fax>+61 8 82227419</fax>
      <email>josh.bardy@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>